Navigation Links
New patient satisfaction study with budesonide/formoterol combination therapy
Date:5/20/2008

Wilmington, DE May 20, 2008 A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM).1 Patients participating in the study were ages 18 years and older with moderate to severe asthma and had been previously treated with inhaled corticosteroids.1 Results were presented today at the International Conference of the American Thoracic Society held in Toronto, May 16-21, 2008.

Results showed that patients receiving budesonide/formoterol combination therapy administered as adjustable dosage reported significantly greater satisfaction on the ATSM overall (p=0.02) than patients receiving fluticasone/salmeterol combination therapy, especially in the categories of feel medication begins to work (p<0.001), dosing management (p<0.001), and timely relief of symptoms (p=0.037).1 Patients receiving budesonide/formoterol combination therapy fixed dose reported significantly greater satisfaction for timely relief of symptoms (p=0.002) and feeling the medication begin to work (p=0.02) compared to patients receiving fluticasone/salmeterol combination therapy.1 Budesonide/formoterol combination therapy is not indicated for adjustable dosing in the U.S.

These data showed that patients treated with budesonide/formoterol combination therapy fixed dose were more satisfied with the timeliness of their symptom relief than those patients treated with fluticasone/salmeterol combination therapy, said lead investigator Richard OConnor, MD, of the University of California-San Diego.


'/>"/>

Contact: Katie Neff
katie.neff@astrazeneca.com
302-885-9960
Edelman Public Relations
Source:Eurekalert

Page: 1

Related medicine news :

1. COPD patients benefit more from pulmonary rehab in earlier stages
2. New treatment gives hope for pulmonary fibrosis patients
3. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
4. Medication may prevent depression in patients with head and neck cancer
5. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
6. Bypass not to blame for heart patients mental decline
7. Long-term cognitive decline in bypass patients not due to surgery
8. Clear racial discrepancies exist among patients with CKD
9. Drug brings relief for many IBS patients who experience constipation
10. Depression, PTSD Common Among Lung Transplant Patient Caregivers
11. Depression and PTSD symptoms in caregivers of lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology: